Background
Methods
Survey development
Data collection
Statistical analysis
Results
Characteristics of oncology specialists and centers
Respondents | ||
---|---|---|
Characteristics | N | % |
Number of respondents | 358 | 90.86 |
Sex | ||
Male | 206 | 57.54 |
Female | 152 | 42.46 |
Specialty | ||
Medical oncologists | 161 | 44.97 |
Oncological surgeons | 101 | 28.21 |
Radiation oncologists | 96 | 26.82 |
Number of years as an oncology clinician | ||
15 years or less | 177 | 49.44 |
More than 15 years | 181 | 50.56 |
Practice setting | ||
General hospital | 126 | 35.20 |
University hospital | 232 | 64.80 |
Practice variation in clinic
Multidisciplinary evaluation
Principles of surgical treatment
Surgery practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists |
p
| |||
---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||
proximal cancer cT2N0M0 | Subtotal gastrectomy | 0.329 | ||||||
Total gastrectomy | 34 | 33.66 | 69 | 42.86 | 37 | 38.54 | ||
Subtotal gastrectomy | 67 | 66.33 | 92 | 57.14 | 59 | 61.46 | ||
antrum cancer cT2N0M0 | Controversial: total or subtotal gastrectomy | < 0.001 | ||||||
Total gastrectomy | 4 | 3.96 | 36 | 22.36 | 33 | 34.38 | ||
Subtotal gastrectomy | 97 | 96.04 | 125 | 79.64 | 63 | 65.63 | ||
Adequate margin | 5 cm | < 0.001 | ||||||
2 cm | 0 | 0 | 4 | 2.48 | 3 | 3.13 | ||
3 cm | 8 | 7.92 | 19 | 11.80 | 8 | 8.33 | ||
4 cm | 14 | 13.86 | 41 | 25.47 | 23 | 23.96 | ||
5 cm | 77 | 76.24 | 58 | 36.02 | 33 | 34.38 | ||
6 cm | 2 | 1.98 | 17 | 10.56 | 14 | 14.58 | ||
unclear | 0 | 0 | 22 | 13.66 | 15 | 15.63 | ||
Extent of lymph nodes dissection | D2 | 0.748 | ||||||
D1 | 0 | 0 | 14 | 8.70 | 8 | 8.33 | ||
D2 | 89 | 88.12 | 94 | 58.39 | 61 | 63.54 | ||
Greater than D2 | 12 | 11.88 | 37 | 22.98 | 15 | 15.63 | ||
unclear | 0 | 0 | 16 | 9.94 | 12 | 12.50 | ||
at least how many regional lymph nodes should be removed | 15 | 0.041 | ||||||
12 | 0 | 0 | 11 | 6.83 | 0 | 0 | ||
15 | 73 | 72.28 | 68 | 42.24 | 44 | 45.83 | ||
20 | 19 | 18.81 | 46 | 28.57 | 39 | 40.63 | ||
30 | 9 | 8.91 | 13 | 8.07 | 0 | 0 | ||
unclear | 0 | 0 | 23 | 14.29 | 13 | 13.54 |
Principles of neoadjuvant treatment
Neoadjuvant practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists |
p
| |||
---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||
adenocarcinoma cT4N0M0 | gastrectomy or preoperative chemotherapy | 0.612 | ||||||
gastrectomy | 40 | 39.60 | 75 | 46.58 | 27 | 28.13 | ||
preoperative chemotherapy | 48 | 47.52 | 72 | 44.72 | 41 | 42.71 | ||
preoperative radiotherapy | 0 | 0 | 0 | 0 | 0 | 0 | ||
preoperative chemoradiation | 13 | 12.87 | 14 | 8.70 | 28 | 29.17 | ||
adenocarcinoma cT2N2M0 | gastrectomy or preoperative chemotherapy | 0.040 | ||||||
gastrectomy | 70 | 69.31 | 77 | 47.83 | 30 | 31.25 | ||
preoperative chemotherapy | 18 | 17.82 | 73 | 45.34 | 38 | 39.58 | ||
preoperative radiotherapy | 0 | 0 | 0 | 0 | 0 | 0 | ||
preoperative chemoradiation | 13 | 12.87 | 11 | 6.83 | 28 | 29.17 | ||
regimen usually used in neoadjuvant setting | ECF(EPI+DDP+5FU) | 0.634 | ||||||
CF(DDP+5FU) | 21 | 20.79 | 29 | 18.01 | 15 | 15.63 | ||
ECF(EPI+DDP+5FU) | 15 | 14.85 | 35 | 21.74 | 14 | 14.58 | ||
fluoropyrimidine(5Fu or Capecitabine) | 24 | 23.76 | 7 | 4.35 | 7 | 7.30 | ||
oxaliplatin based regimen | 23 | 22.77 | 63 | 39.13 | 35 | 36.46 | ||
irinotecan based regimen | 12 | 11.88 | 5 | 3.11 | 9 | 9.38 | ||
paclitaxel or docetaxel based regimen | 6 | 5.94 | 22 | 13.66 | 16 | 16.67 | ||
combination of above or other | 0 | 0 | 0 | 0 | 0 | 0 | ||
how long neoadjuvant chemotherapy last | 3 cycles, about 2 months | 0.213 | ||||||
< 1 m | 21 | 20.79 | 19 | 11.80 | 8 | 8.33 | ||
1-3 m | 76 | 75.25 | 127 | 78.88 | 79 | 82.29 | ||
> 3 m | 4 | 3.96 | 15 | 9.32 | 9 | 9.38 |
Principles of adjuvant treatment
Adjuvant practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists |
p
| |||
---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||
moderately differentiated adenocarcinoma pT4N0M0 after gastrectomy | postoperative chemoradiation | 0.007 | ||||||
observe without postoperative treatment | 19 | 18.81 | 0 | 0 | 0 | 0 | ||
postoperative chemotherapy | 57 | 56.44 | 102 | 63.35 | 26 | 27.08 | ||
postoperative radiotherapy | 0 | 0 | 0 | 0 | 7 | 7.29 | ||
postoperative chemoradiation | 25 | 24.75 | 59 | 36.65 | 63 | 65.63 | ||
moderately differentiated adenocarcinoma pT4N0M0 after gastrectomy | Systemic chemotherpy | < 0.001 | ||||||
Systemic chemotherapy | 73 | 72.28 | 89 | 55.28 | 75 | 78.13 | ||
Intraperitoneal chemotherapy(IP) | 0 | 0 | 0 | 0 | 0 | 0 | ||
Systemic chemotherapy+IP | 28 | 27.72 | 72 | 44.72 | 21 | 21.88 | ||
Other | 0 | 0 | 0 | 0 | 0 | 0 | ||
moderately differentiated adenocarcinoma invaded muscularis and vascular without metastasis in the 16 removed regional lymph nodes | postoperative chemotherapy | 0.044 | ||||||
observe without postoperative treatment | 41 | 40.59 | 37 | 22.98 | 26 | 27.08 | ||
postoperative chemotherapy | 46 | 45.54 | 73 | 45.34 | 38 | 39.58 | ||
postoperative radiotherapy | 0 | 0 | 0 | 0 | 13 | 13.54 | ||
postoperative chemoradiation | 14 | 13.86 | 51 | 31.68 | 19 | 19.79 | ||
other | 0 | 0 | 0 | 0 | 0 | 0 | ||
poor differentiated adenocarcinoma invaded muscularis without metastasis in the 16 removed regional lymph nodes | postoperative chemotherapy | 0.053 | ||||||
observe without postoperative treatment | 52 | 51.49 | 21 | 13.04 | 17 | 17.71 | ||
postoperative chemotherapy | 43 | 42.57 | 140 | 86.96 | 58 | 60.42 | ||
postoperative radiotherapy | 3 | 2.97 | 0 | 0 | 0 | 0 | ||
postoperative chemoradiation | 3 | 2.97 | 0 | 0 | 21 | 21.88 | ||
other | 0 | 0 | 0 | 0 | 0 | 0 | ||
well differentiated adenocarcinoma invaded muscularis without metastasis in the 6 removed regional lymph nodes | observe without postoperative treatment | 0.020 | ||||||
observe without postoperative treatment | 29 | 28.71 | 68 | 42.24 | 36 | 37.50 | ||
postoperative chemotherapy | 66 | 65.35 | 61 | 37.89 | 36 | 37.50 | ||
postoperative radiotherapy | 0 | 0 | 0 | 0 | 5 | 5.21 | ||
postoperative chemoradiation | 6 | 5.94 | 32 | 19.88 | 19 | 19.79 | ||
other | 0 | 0 | 0 | 0 | 0 | 0 | ||
when begin adjuvant chemotherapy after gastrectomy | NA | 0.233 | ||||||
1-2 w | 13 | 12.87 | 28 | 17.39 | 11 | 11.46 | ||
3-4 w | 82 | 81.19 | 133 | 82.61 | 79 | 82.29 | ||
5-6 w | 4 | 3.96 | 0 | 0 | 6 | 6.25 | ||
≥ 6 w | 2 | 1.98 | 0 | 0 | 0 | 0 | ||
regimen usually used in adjuvant setting (without neoadjuvant chemotherapy) | CF(DDP+5FU) or fluoropyrimidine(5Fu or Capecitabine) | 0.383 | ||||||
CF(DDP+5FU) | 18 | 17.82 | 21 | 13.04 | 12 | 12.50 | ||
ECF(EPI+DDP+5FU) | 12 | 11.88 | 25 | 15.53 | 7 | 7.29 | ||
fluoropyrimidine(5Fu or Capecitabine) | 12 | 11.88 | 11 | 6.83 | 11 | 11.46 | ||
oxaliplatin based regimen | 34 | 33.66 | 69 | 42.86 | 44 | 45.83 | ||
irinotecan based regimen | 20 | 19.80 | 8 | 4.97 | 9 | 9.38 | ||
paclitaxel or docetaxel based regimen | 5 | 4.95 | 24 | 14.91 | 8 | 8.33 | ||
combination of above or other | 0 | 0 | 3 | 1.86 | 5 | 5.21 | ||
how long adjuvant chemtherapy last | NA | 0.220 | ||||||
1-3 m | 11 | 10.89 | 2 | 1.24 | 11 | 11.46 | ||
4-6 m | 71 | 70.30 | 144 | 89.44 | 63 | 65.63 | ||
7-9 m | 7 | 6.93 | 3 | 1.86 | 7 | 7.29 | ||
10-12 m | 5 | 4.95 | 5 | 3.11 | 8 | 8.33 | ||
≥ 12 m | 3 | 2.97 | 4 | 2.48 | 7 | 7.29 | ||
3-6 m in the first year, then 2-3 m annually for 2-3 y | 4 | 3.96 | 3 | 1.86 | 0 | 0 | ||
other | 0 | 0 | 0 | 0 | 0 | 0 |
Principles of follow-up
Follow-up practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists |
p
| |||
---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||
how often follow-up | Every 4-6 m for 3 y, then annually | 0.086 | ||||||
Every 4-6 m for 3 y, then annually | 9 | 8.91 | 18 | 11.18 | 7 | 7.29 | ||
Every 4-6 m for 5 y, then annually | 13 | 12.87 | 25 | 15.53 | 11 | 11.46 | ||
Every 2-3 m for 3 y, then annually | 64 | 63.37 | 94 | 58.39 | 63 | 65.63 | ||
Every 2-3 m for 5 y, then annually | 12 | 11.88 | 19 | 11.80 | 14 | 14.58 | ||
other | 3 | 2.97 | 5 | 3.11 | 1 | 3.13 | ||
which included in the follow-up (multiple answers) | Complete history and physical examination for all the patients, CBC, platetets, radiologic imaging or endoscopy as clinically indicated, monitor Vit B12 for proximal or total gastrectomy patitnts | 0.371 | ||||||
Complete history and physical examination | 101 | 100 | 161 | 100 | 96 | 100 | ||
CBC, Hb, platetets | 101 | 100 | 161 | 100 | 96 | 100 | ||
Hepatic and renal function | 101 | 100 | 154 | 95.65 | 91 | 94.79 | ||
Endoscopy | 92 | 91.09 | 123 | 76.40 | 86 | 89.58 | ||
Chest CT | 46 | 45.54 | 156 | 96.89 | 88 | 91.67 | ||
Abdominal CT | 101 | 100 | 160 | 99.38 | 93 | 96.88 | ||
Vit B12 | 29 | 28.71 | 34 | 21.12 | 26 | 27.08 | ||
Trace elements and electrolytes | 18 | 17.82 | 29 | 18.01 | 19 | 19.79 | ||
Other | 0 | 0 | 0 | 0 | 0 | 0 | ||
which recommended as food supplementation (multiple answers)? | Vit B12 for proximal or total gastrectomy patitnts | 0.786 | ||||||
Iron | 101 | 100 | 159 | 98.76 | 82 | 85.42 | ||
Trace elements and electrolytes | 71 | 70.30 | 128 | 79.50 | 74 | 77.08 | ||
Vit B12 | 101 | 100 | 161 | 100 | 95 | 98.96 | ||
Other | 0 | 0 | 0 | 0 | 0 | 0 |
Principles of palliative treatment
Advanced practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists |
p
| |||
---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||
adenocarcinoma with solitary liver metastases | Systemic chemotherpy | 0.443 | ||||||
Systemic chemotherpy | 4 | 3.96 | 7 | 4.35 | 5 | 5.21 | ||
Liver lesion resection | 8 | 7.92 | 16 | 9.94 | 5 | 5.21 | ||
TACE | 10 | 9.90 | 21 | 13.04 | 15 | 15.63 | ||
Liver lesion resection + systemic chemotherpy | 79 | 78.22 | 117 | 72.67 | 68 | 70.83 | ||
Other | 0 | 0 | 0 | 0 | 3 | 3.13 | ||
adenocarcinoma with large quantity of ascites | Systemic chemotherpy | 0.210 | ||||||
Systemic chemotherapy | 3 | 2.97 | 2 | 1.24 | 2 | 2.08 | ||
intraperitoneal chemotherapy(IP) | 4 | 3.96 | 6 | 3.73 | 5 | 5.21 | ||
Systemic chemotherapy+IP | 94 | 93.07 | 153 | 95.03 | 89 | 92.71 | 0.254 | |
Other | 0 | 0 | 0 | 0 | 0 | 0 | ||
lungs metastases | Paclitaxel or docetaxel based regime or ECF(EPI+DDP+5FU) | 0.070 | ||||||
CF(DDP+5FU) | 2 | 1.98 | 3 | 1.86 | 1 | 1.04 | ||
ECF(EPI+DDP+5FU) | 17 | 16.83 | 23 | 14.29 | 9 | 9.38 | ||
Fluoropyrimidine(5Fu or Capecitabine) | 13 | 12.87 | 12 | 7.45 | 14 | 14.58 | ||
Oxaliplatin based regimen | 33 | 32.67 | 51 | 31.68 | 25 | 26.04 | ||
Irinotecan based regimen | 9 | 8.91 | 22 | 13.66 | 15 | 15.63 | ||
Paclitaxel or docetaxel based regime | 25 | 24.75 | 46 | 28.57 | 29 | 30.21 | ||
Combination of above or other | 2 | 1.98 | 4 | 2.48 | 3 | 3.13 | ||
lungs metastases, failure after ECF(EPI+DDP+5FU) | Change regimen and continue chemotherapy | |||||||
Change regimen and continue chemotherapy | 101 | 100 | 156 | 96.89 | 83 | 86.46 | 0.137 | |
Best supportive care | 0 | 0 | 2 | 1.24 | 9 | 9.38 | ||
Other | 0 | 0 | 3 | 1.86 | 4 | 4.17 | ||
lungs metastases, failure after both ECF and Paclitaxel+DDP | Change regimen and continue chemotherapy | 0.351 | ||||||
Change regimen and continue chemotherapy | 86 | 85.15 | 122 | 75.78 | 60 | 62.50 | ||
Best supportive care | 13 | 12.87 | 35 | 21.74 | 31 | 32.29 | ||
Other | 2 | 1.98 | 4 | 2.48 | 5 | 5.21 | ||
lungs metastases, failure after both ECF and Paclitaxel+DDP, PS 3 | Best supportive care | 0.222 | ||||||
Change regimen and continue chemotherapy | 18 | 17.82 | 15 | 9.32 | 9 | 9.38 | ||
Best supportive care | 79 | 78.22 | 136 | 84.47 | 81 | 84.38 | ||
Other | 4 | 3.96 | 10 | 6.21 | 6 | 6.25 |